Effectiveness of Ledipasvir/Sofosbuvir and Predictors of Treatment Failure in Members with Hepatitis C Genotype 1: A Retrospective Cohort Study in a Medicaid Population

Monday, March 27, 2017
Poster of HCV treatment rates
George Kouris, PharmD
University of Massachusetts Medical School
Tasmina Hydery, PharmD, MBA, CGP
University of Massachusetts Medical School
Bonnie Greenwood, PharmD, BCPS
University of Massachusetts Medical School
Pavel Lavitas, PharmD, BCPS
University of Massachusetts Medical School
Caroline J. Alper, MD
University of Massachusetts Medical School
Mylissa Price, MPH, BS, RPh
University of Massachusetts Medical School
Karen Clements, ScD
University of Massachusetts Medical School
Kimberly Lenz, PharmD
University of Massachusetts Medical School
Paul L. Jeffrey, PharmD
University of Massachusetts Medical School

An evaluation of the effectiveness of HCV genotype 1 treatment with Harvoni® (ledipasvir/sofosbuvir) as measured by a sustained virological response (SVR) of 12 weeks in the MassHealth fee-for-service and Primary Care Clinician plan population. The analysis concluded that treatment was associated with a a high rate of SVR12, which means that Hepatitis C is not detected in the blood after 12 weeks.

Conference 
Academy of Managed Care & Specialty Pharmacy Annual Conference 2017